Mauna Kea Technologies manufactures Cellvizio Lab, confocal probe based imaging system, providing cellular-level images with minimal invasiveness for longitudinal studies.
Accelerate to discover
Related topics
InAlyzer to evaluate G6PD activity in relation with frailty
Mar 28, 2023
InAlyzer is body densitometry instrument for lab animals, equipped with 2 X-Ray sources and able to provide valuable...
Cardiomyocyte isolation using Cellenion’s cellenONE instrument
Mar 24, 2023
The cellenONE platform is ideal for the isolation of fragile and heterogeneous cell size populations, such as...
ACCELA educational webinar: Unlocking Spatial Biology with RareCyte Orion
Mar 16, 2023
Experience Spatial Biology with Orion Multiplex Imaging. Orion is a benchtop, high...
Recorded webinar: Anesthesia Considerations in Small Animal Imaging
Mar 13, 2023
Anesthesia settings and operation of Optical Imaging Systems: methods, animal handling, safety and regulatory...
Introducing Cytek Human Leukocyte Kit, the first ever 15-color lyse no-wash assay
Mar 13, 2023
This kit has been designed to enumerate all major leukocyte subsets and it mirrors and expands on those identified in a...
Immunofluorescence Imaging for Rare Cell Detection with CyteFinder II
Mar 7, 2023
CyteFinder II Instruments are high speed, whole slide imaging systems with options for liquid biopsy analysis and...
NanoCellect Webinar: Optimizing the Cell Line Development Process with Microfluidic Cell Sorting
Mar 3, 2023
Single-cell selection and cloning are required for bioengineering workflows such as antibody production, cell therapy,...
New Kit for Bacterial analysis expands capability of Guava Muse flow cytometer
Feb 20, 2023
With the Guava Muse cell analyzer, you can now achieve highly quantitative results at a fraction of the price, effort,...
Nov 23, 2017
Nonalcoholic fatty liver disease (NAFLD) directly affects 10–30% of the human population and is characterized by pathological alterations ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and irreversible cirrhosis. NAFLD is considered a hepatic component of metabolic syndromes and is thus strongly associated with metabolic diseases such as obesity, insulin resistance, hypertension, and dyslipidemia. The prevalence of NAFLD is strongly associated with obesity and the metabolic complications of over-nutrition, which usually accompany visceral obesity. Visceral obesity is particularly associated with NAFLD. The amount of visceral fat is directly linked to the severity of liver inflammation and fibrosis in NAFLD. Human and animal studies indicate that NAFLD is strongly associated with VAT inflammation and elevated circulating inflammatory factors such as inflammatory adipokines and lipids. It is reasonable that targeting visceral adipose tissue (VAT) can contribute to the treatment and prevention of NAFLD. Accordingly, we thought it plausible that the anti-angiogenic-induced VAT loss may attenuate NAFLD during obesity.
Visualization of real-time visceral adipose tissue vasculature was performed using an FCFM imaging system (Cellvizio, Mauna Kea Technologies) with excitation and emission wavelengths of 488 and 520 nm, respectively.
Get more info
Brand profile
Mauna Kea Technologies manufactures Cellvizio Lab, confocal probe based imaging system, providing cellular-level images with minimal invasiveness for longitudinal studies.
More info at:
www.cellviziolab.com/